Drug intelligence / Profile preview

TY-3200

Development stage: Preclinical
Lead developer: TYK Medicines
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

TY-3200 is a preclinical-stage proteolysis-targeting chimera (PROTAC) developed by Zhejiang Tongyuan Kang Medicine (TYK Medicines) for the treatment of non-small cell lung cancer (NSCLC). It is designed to selectively target and degrade the epidermal growth factor receptor (EGFR) protein. By utilizing the ubiquitin-proteasome system, TY-3200 aims to overcome resistance mechanisms associated with traditional EGFR tyrosine kinase inhibitors (TKIs), potentially offering a new therapeutic approach for patients with EGFR-mutant NSCLC.

Targets

CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)Epidermal growth factor receptor (mutant)

Beyond the preview

Go deeper on TY-3200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TY-3200.

Explore the full profile